Our Housing team are delighted following a formal tender procurement process to have been appointed to three lots under the new multi-million-pound legal services framework for The Riverside Group.
However, sometimes epilepsy medication can cause harm to the patient or even their unborn child. This is particularly the case with Sodium Valproate, which goes by the brand names Epilim and Depakote.
Next week, women whose children have been harmed by this drug will give evidence to a European-wide safety review that will examine whether warnings about risks to unborn babies are strong enough.
All medication – not just Sodium Valproate – of course, has side-effects and risks. These must be weighed up against the benefits of medication. In order to weigh up the pros and cons, the patient and treating team must know what the risks and side-effects could be. Worryingly, this has not always been the case with Epilim – and I can say that from personal experience when I took the drug some years ago.
Sodium Valproate/Epilim used to be a very common medication for people with epilepsy, but for many years it has been known that Epilim increases the risk of a baby born to a mother taking Epilim suffering physical abnormalities and cognitive impairments. Babies exposed to Epilim/Sodium Valproate in the womb have a 10% chance of developing physical abnormalities and a 4 in 10 chance of developing cognitive problems, such as learning disabilities and autism. Evidence of this risk emerged back in the 1980s, but for years many patients have not been told about the risk. Medical advice now is that Epilim/Sodium Valproate should not be used during pregnancy unless there is no safer alternative and only after a careful discussion of the risks.
There is currently a group action in France against the drug company which makes Sodium Valproate, Sanofi. In the past, there was also a group action in the UK.
Whilst drug companies must give comprehensive and clear advice on all side-effects and potential risks, the responsibility to inform a patient and weigh up the pros and cons does not fall solely to the drug company. A patient's treating doctor must advise the patient about the side-effects and risks. The doctor might have been negligent if she fails to do so.
Doctors are under a duty to take reasonable care to ensure that the patient is aware of any material risks involved in any recommended treatment and of any reasonable alternative or variant treatments. A significant risk is one which would affect the judgment of a reasonable patient. Surely a 10% risk of a baby developing physical abnormalities and a 25% risk of cognitive problems is a significant risk that doctors should make all patients aware of so that they can make their own decision about their life and that of future children.
Necrotising Fasciitis, more commonly known as the ‘flesh-eating disease’, is a significant medical condition that requires urgent treatment.
Many of us who have been following the unfolding Inquest, are not surprised that the Coroner found gross and significant failures on the part of those caring for him.
Transferring out of SHPS will not be suitable for every housing association. So what should housing associations do?
In all the action to remove defective cladding, leaseholders have been the elephant in the room. Whilst social landlords might have adopted a wait and see approach private landlords do not have that luxury.
We welcome the Labour Party’s commitment to doubling the size of the co-operative economy. We wholeheartedly support the ambition to grow this vitally important part of the economy.
It was first referred to in the Charities Act 2006 (which was subsequently replaced by the Charities Act 2011) but it has finally been announced that charitable companies are able to convert to a charitable incorporated organisation (“CIO”).
The Private Members Bill Homes (Fitness for Human Habitation and Liability for Housing Standards) Bill 2017-19 now has Government support and was debated at second reading on Friday 19 January 2018.
In short - yes. This is a common question in personal injury or clinical negligence claims and has recently come before the High Court in judicial review proceedings.
GDPR The General Data Protection Regulations (GDPR) will come into force on 25 May 2018 and bring changes to the rules governing data protection and the requirements placed on organisations which control or process personal data.
To receive invitations to our events, as well as information and articles on legal issues and sector developments that are of interest to you, please sign up to Newsroom.